News
10-21-2018, 09:45 PM
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
More... (https://www.news-medical.net/news/20181022/Shorter-course-of-trastuzumab-could-be-an-option-for-women-with-HER22b-early-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20181022/Shorter-course-of-trastuzumab-could-be-an-option-for-women-with-HER22b-early-breast-cancer.aspx)